CVS Health faces Florida probe into Caremark, shares trade near analyst targets
26.06.2026 - 12:56:50 | ad-hoc-news.de
By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 12:56.
CVS Health Corp. (US1266501006) comes under fresh regulatory scrutiny. Florida’s Attorney General has opened an investigation into the group’s Caremark pharmacy benefit management unit, while CVS Health shares continue to trade on the NYSE close to prevailing analyst targets.
Florida investigates Caremark practices
According to a detailed summary of the case, the Florida Attorney General is examining allegations that Caremark engaged in anticompetitive practices that may have hurt independent pharmacies. The probe focuses on claims that patients were steered toward CVS-owned pharmacies, that reimbursement terms favored CVS entities, and that audit procedures may have disadvantaged competing outlets.
The investigation adds to broader U.S. scrutiny of pharmacy benefit managers, a group that includes CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth’s OptumRx as major sector peers. For CVS Health, the case is a reminder that regulatory risk around PBM business models remains live even as the company pursues its integrated healthcare strategy.
Shares near consensus price targets
On the equity side, CVS Health shares trade broadly in line with average analyst price targets cited in recent consensus work. One analysis puts the stock at about US$104.66, close to an average analyst target of around US$105.38, implying only a narrow gap between current valuation and the Street’s near-term expectations.
The same source highlights a materially higher intrinsic value estimate, suggesting that CVS Health may screen as undervalued versus certain fundamental models, even as the shares change hands near the sell-side target range. Sector peers such as UnitedHealth Group and Cigna have also drawn valuation debates as investors weigh regulatory headwinds against the defensive characteristics of large U.S. healthcare names.
Background and price data on CVS Health Corp.
Further articles and quote information on CVS Health shares provide additional context on valuation, regulation and the integrated healthcare strategy.
How CVS Health makes its money
CVS Health generates revenue across retail pharmacies, insurance and PBM operations. The company’s Caremark PBM unit manages prescription drug benefits for employers, health plans and government entities, while the Aetna division offers health insurance products, and CVS Pharmacy locations provide front-store and prescription sales nationwide.
Where the shares trade today
CVS Health Corp. shares (US1266501006) trade on the NYSE; recent quotes place the stock around the low-US$100 range, with price snapshots such as US$104.66 used in current valuation comparisons. These levels frame the discussion on whether regulatory probes and PBM headwinds are fully reflected in the market price.
Key data on the CVS Health shares
- Company: CVS Health Corp.
- ISIN: US1266501006
- WKN: 859034
- Ticker: CVS
- Trading venue: NYSE
- Price (as of 2026-06-25, 21:00): 104.66 USD
- Market cap: around 130 billion USD (as of 2026-06-25)
- Sector / industry: Health Care / Managed Health Care
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.
